Overview

RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2025-12-25

Target enrollment:

Participant gender:

Summary

As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the treatment of breast cancer and gastric cancer with HER2 amplification or overexpression. In colorectal cancer, HER2 as a target has also been focused in recent years.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Celecoxib